How to appeal a Humana amyloidosis (cardiac attr + al) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for amyloidosis (cardiac attr + al)

Cited policy: Humana Off-Label Diflunisal for TTR Stabilization (Bridge / Salvage)

Off-label use coverage requires: (a) confirmed ATTR amyloidosis diagnosis, (b) failed access to FDA-approved TTR-directed therapy (tafamidis denied / acoramidis denied / vutrisiran denied / patient unable to afford), (c) eGFR >=30 mL/min/1.73m², (d) no contraindication to NSAID (no active GI bleed, no severe HF decompensation, monitored renal/BP). Cardiologist Rx, monitoring at 4-8 wk.

How Humana denies amyloidosis (cardiac attr + al) — and how to counter it

Where Humana pushes back: 1) Off-label / not FDA-approved for ATTR; 2) NSAID-class contraindicated in HF; 3) Use tafamidis or acoramidis instead.

Counter-arguments that hold up: Berk JAMA 2013 — RCT of diflunisal in ATTR-FAP demonstrated slowed neurologic progression via TTR stabilization; mechanism extends to cardiac amyloid. Off-label use is medically appropriate when FDA-approved alternatives are denied or unaffordable (tafamidis ~$225,000/yr, acoramidis similar). NSAID risks managed with eGFR >=30 cutoff, BP/renal monitoring at 4-8 wk, and PPI co-administration. AHA 2020 Scientific Statement + ESC 2023 explicitly acknowledge diflunisal as off-label TTR stabilizer when access to FDA agents is barrier. Bridge therapy until FDA-approved TTR stabilizer or silencer access secured.

What Humana typically denies for amyloidosis (cardiac attr + al)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For amyloidosis (cardiac attr + al), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the amyloidosis (cardiac attr + al) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Vyndaqel / Vyndamax (tafamidis)
• Attruby (acoramidis)
• Amvuttra (vutrisiran) ATTR-CM
• Onpattro (patisiran)
• Wainua (eplontersen)
• D-VCd for AL

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.